Scientific Reports (Aug 2021)

Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis

  • Diana Prieto-Peña,
  • Sara Remuzgo-Martínez,
  • Fernanda Genre,
  • Verónica Pulito-Cueto,
  • Belén Atienza-Mateo,
  • Javier Llorca,
  • Belén Sevilla-Pérez,
  • Norberto Ortego-Centeno,
  • Ana Marquez,
  • Leticia Lera-Gómez,
  • María Teresa Leonardo,
  • Ana Peñalba,
  • Javier Narváez,
  • Luis Martín-Penagos,
  • Emilio Rodrigo,
  • José A. Miranda-Filloy,
  • Luis Caminal-Montero,
  • Paz Collado,
  • Javier Sánchez Pérez,
  • Diego de Argila,
  • Esteban Rubio,
  • Manuel León Luque,
  • Juan María Blanco-Madrigal,
  • Eva Galíndez-Agirregoikoa,
  • Oreste Gualillo,
  • Javier Martín,
  • Santos Castañeda,
  • Ricardo Blanco,
  • Miguel A. González-Gay,
  • Raquel López-Mejías

DOI
https://doi.org/10.1038/s41598-021-95762-5
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Cytokines signalling pathway genes are crucial factors of the genetic network underlying the pathogenesis of Immunoglobulin-A vasculitis (IgAV), an inflammatory vascular condition. An influence of the interleukin (IL)33- IL1 receptor like (IL1RL)1 signalling pathway on the increased risk of several immune-mediated diseases has been described. Accordingly, we assessed whether the IL33-IL1RL1 pathway represents a novel genetic risk factor for IgAV. Three tag polymorphisms within IL33 (rs3939286, rs7025417 and rs7044343) and three within IL1RL1 (rs2310173, rs13015714 and rs2058660), that also were previously associated with several inflammatory diseases, were genotyped in 380 Caucasian IgAV patients and 845 matched healthy controls. No genotypes or alleles differences were observed between IgAV patients and controls when IL33 and IL1RL1 variants were analysed independently. Likewise, no statistically significant differences were found in IL33 or IL1RL1 genotype and allele frequencies when IgAV patients were stratified according to the age at disease onset or to the presence/absence of gastrointestinal (GI) or renal manifestations. Similar results were disclosed when IL33 and IL1RL1 haplotypes were compared between IgAV patients and controls and between IgAV patients stratified according to the clinical characteristics mentioned above. Our results suggest that the IL33-IL1RL1 signalling pathway does not contribute to the genetic network underlying IgAV.